RazorSharpDNA 🧬 (@RazorSharpDNA) header
RazorSharpDNA 🧬 (@RazorSharpDNA) profile picture

Biotech, explained by the science 🧬 Gene editing, readouts, M&A, AI firsts, longevity, psychedelics. Primary sources, honest caveats. Not 💵 advice.

Joined November 2011
Depression scores split from placebo by Day 2, and the gap held to Week 12. $HELP HLP003 (deuterated psilocin) on top of an antidepressant, Phase 3, 222 patients: MADRS 7.6 points better at Week 6, remission 50.9% vs 18.2%. Second pivotal reads 4Q 2027. Will it replicate?
3
4
226
Up to 8x more bile acids left in the blood, from changing one RNA letter. $PRQR AX-0810 recruits the cell's own ADAR enzyme to edit NTCP, the liver's bile acid intake pump. 22 healthy volunteers, no SAEs. Full 9 mg/kg data in December. Will it hold in biliary atresia?
1
341
Biotech, explained by the science. Gene editing, clinical readouts, M&A, AI and robotics firsts, longevity and psychedelic medicines. Hard numbers, honest caveats. 🧬
174
SMID biotech & gene editing, explained. Readouts, hard numbers, honest caveats. 🧬
1
176
2 of 2 kidneys responded by Month 6. $FATE FT819 is an off the shelf CD19 CAR T from a stem cell bank, not the patient's cells. One dose. Urine protein fell about 50%. n=2 so far 🤷‍♂️ Can inventory CAR T reset lupus nephritis?
2
1
3
618
One drug: 0 of 14 major responses. Add a second: 4 of 14 colon tumors had no viable cancer at surgery. $AGEN's botensilimab plus balstilimab, given before surgery in MSS colon cancer. No combo patient relapsed at 19.2 months median. 14 per arm, not randomized. Will it hold?
1
118
$182M in one quarter, a year into launch. $PTCT's oral PKU drug Sephience grew 20% vs Q2, with 2,000+ patients on it. Product sales guidance is now $960M to $990M. Next: a Q4 BLA for ST-920, a one dose Fabry gene therapy. Ex-US was only $37M. How much room is left abroad?
151